Autoimmunity and dysmetabolism of human acquired immunodeficiency syndrome

Immunologic Research

Volumn 64, Issue 3, 2016, Pages 641-652

  Huang, Yan Mei ^a   Hong, Xue Zhi ^a   Xu, Jia Hua ^b   Luo, Jiang Xi ^a   Mo, Han You ^a   Zhao, Hai Lu ^a  

^a GUILIN MEDICAL UNIVERSITY   (China)

^b Fangchenggang Hospital of Traditional Chinese Medicine   (China)

Author keywords

Acquired immunodeficiency syndrome; Autoimmunity; Human immunodeficiency virus vaccine; Immunodeficiency; Metabolism; Regulatory T cells

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; HAPTEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; TOLL LIKE RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AUTOIMMUNITY; CATABOLISM; CYTOTOXIC T LYMPHOCYTE; DRUG TREATMENT FAILURE; FEVER; FOOD; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; LYMPHOCYTE FUNCTION; METABOLIC DISORDER; MOLECULAR MIMICRY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; STEM CELL TRANSPLANTATION; WEIGHT REDUCTION; CD4+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); HOMEOSTASIS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; KAPOSI SARCOMA; METABOLISM; PNEUMOCYSTIS PNEUMONIA; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; AUTOANTIBODIES; AUTOIMMUNITY; CD4-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; HIV-1; HOMEOSTASIS; HUMANS; PNEUMONIA, PNEUMOCYSTIS; SARCOMA, KAPOSI; WEIGHT LOSS;

EID: 84949943000     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-015-8767-5     Document Type: Review

References (172)

1. Centers for Disease Control. Pneumocystis pneumonia—Los Angeles. MMWR Morb Mortal Wkly Rep. 1981;30(21):250–2.
2. Centers for Disease Control. Kaposi’s sarcoma and Pneumocystis pneumonia among homosexual men—New York City and California. MMWR Morb Mortal Wkly Rep. 1981;30(25):305–8.
3. Curra JW. Epidemiologic aspects of the current outbreak of Kaposi’s sarcoma and opportunistic infections. N Engl J Med. 1982;306(4):248–52. doi:10.1056/NEJM198201283060431.
4. Fainstein V, Bolivar R, Mavligit G, Rios A, Luna M. Disseminated infection due to Mycobacterium avium-intracellulare in a homosexual man with Kaposi’s sarcoma. J Infect Dis. 1982;145(4):586.
5. Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT, Wolf RA, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med. 1981;305(24):1425–31. doi:10.1056/NEJM198112103052401.
6. Masur H, Michelis MA, Greene JB, Onorato I, Stouwe RA, Holzman RS, et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med. 1981;305(24):1431–8. doi:10.1056/NEJM198112103052402.
7. Gallo RC, Sarin PS, Gelmann EP, Robert-Guroff M, Richardson E, Kalyanaraman VS, et al. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science. 1983;220(4599):865–7.
8. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983;220(4599):868–71.
9. Goodson P. Questioning the HIV–AIDS hypothesis: 30 years of dissent. Front Public Health. 2014;2:154. doi:10.3389/fpubh.2014.00154.
10. Gelmann EP, Popovic M, Blayney D, Masur H, Sidhu G, Stahl RE, et al. Proviral DNA of a retrovirus, human T-cell leukemia virus, in two patients with AIDS. Science. 1983;220(4599):862–5.
11. Duesberg P. HIV is not the cause of AIDS. Science. 1988;241(4865):514–7.
12. Duesberg PH. AIDS acquired by drug consumption and other noncontagious risk factors. Pharmacol Ther. 1992;55(3):201–77.
13. Mallery SR, Pei P, Landwehr DJ, Clark CM, Bradburn JE, Ness GM, et al. Implications for oxidative and nitrative stress in the pathogenesis of AIDS-related Kaposi’s sarcoma. Carcinogenesis. 2004;25(4):597–603. doi:10.1093/carcin/bgh042bgh042.
14. Papadopulos-Eleopulos E, Turner VF, Papadimitriou JM, Alfonso H, Page BA, Causer D, et al. High rates of HIV seropositivity in Africa—alternative explanation. Int J STD AIDS. 2003;14(6):426–7. doi:10.1258/095646203765371330.
15. Papadopulos-Eleopulos E, Turner VF, Papadimitriou JM, Bialy H. AIDS in Africa: distinguishing fact and fiction. World J Microbiol Biotechnol. 1995;11(2):135–43. doi:10.1007/BF00704634.
16. Centers for Disease Control. Current trends update on acquired immune deficiency syndrome (AIDS)—United States. MMWR Morb Mortal Wkly Rep. 1982;31(37):4.
17. Siegal FP, Lopez C, Hammer GS, Brown AE, Kornfeld SJ, Gold J, et al. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med. 1981;305(24):1439–44. doi:10.1056/NEJM198112103052403.
18. Papadopulos-Eleopulos E. A mitotic theory. J Theor Biol. 1982;96(4):741–57.
19. Malatzky-Goshen E, Shoenfeld Y. AIDS and autoimmunity. Autoimmunity. 1989;3(3):201–12.
20. Lane HC, Fauci AS. Immunologic abnormalities in the acquired immunodeficiency syndrome. Annu Rev Immunol. 1985;3:477–500. doi:10.1146/annurev.iy.03.040185.002401.
21. Dalgleish AG. What is the role of autoimmunity in AIDS? Autoimmunity. 1993;15(3):237–44.
22. Bourinbaiar AS, Abulafia-Lapid R. Autoimmunity, alloimmunization and immunotherapy of AIDS. Autoimmun Rev. 2005;4(6):403–9. doi:10.1016/j.autrev.2005.01.004.
23. Vega MA, Guigo R, Smith TF. Autoimmune response in AIDS. Nature. 1990;345(6270):26. doi:10.1038/345026a0.
24. Gow PJ, Mutimer D. Liver transplantation for an HIV-positive patient in the era of highly active antiretroviral therapy. AIDS. 2001;15(2):291–2.
25. Holland HK, Saral R, Rossi JJ, Donnenberg AD, Burns WH, Beschorner WE, et al. Allogeneic bone marrow transplantation, zidovudine, and human immunodeficiency virus type 1 (HIV-1) infection. Studies in a patient with non-Hodgkin lymphoma. Ann Intern Med. 1989;111(12):973–81.
26. Contu L, La Nasa G, Arras M, Pizzati A, Vacca A, Carcassi C, et al. Allogeneic bone marrow transplantation combined with multiple anti-HIV-1 treatment in a case of AIDS. Bone Marrow Transplant. 1993;12(6):669–71.
27. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005;191(5):654–65. doi:10.1086/428404.
28. Gilbert PB, Ackers ML, Berman PW, Francis DP, Popovic V, Hu DJ, et al. HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine. J Infect Dis. 2005;192(6):974–83. doi:10.1086/432734.
29. Levine AM, Groshen S, Allen J, Munson KM, Carlo DJ, Daigle AE, et al. Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 Immunogen: long-term follow-up. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;11(4):351–64.
30. Lifson JD, Rossio JL, Piatak M Jr, Bess J Jr, Chertova E, Schneider DK, et al. Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins. AIDS Res Hum Retrovir. 2004;20(7):772–87. doi:10.1089/0889222041524661.
31. Pion M, Jaramillo-Ruiz D, Martinez A, Munoz-Fernandez MA, Correa-Rocha R. HIV infection of human regulatory T cells downregulates Foxp3 expression by increasing DNMT3b levels and DNA methylation in the FOXP3 gene. AIDS. 2013;27(13):2019–29. doi:10.1097/QAD.0b013e32836253fd.
32. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133(5):775–87. doi:10.1016/j.cell.2008.05.009.
33. Yang X, Ma RC, So WY, Ko GT, Kong AP, Zhao H, et al. White blood cell count and renin-angiotensin system inhibitors for the risk of cancer in type 2 diabetes. Diabetes Res Clin Pract. 2009;87(1):117–25. doi:10.1016/j.diabres.2009.10.012.
34. Duggal P, Guo X, Haque R, Peterson KM, Ricklefs S, Mondal D, et al. A mutation in the leptin receptor is associated with Entamoeba histolytica infection in children. J Clin Invest. 2011;121(3):1191–8. doi:10.1172/JCI45294.
35. Odegaard JI, Chawla A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science. 2013;339(6116):172–7. doi:10.1126/science.1230721.
36. Grunfeld C, Feingold KR. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl J Med. 1992;327(5):329–37. doi:10.1056/NEJM199207303270506.
37. Macallan DC, Griffin GE. Metabolic disturbances in AIDS. N Engl J Med. 1992;327(21):1530–1. doi:10.1056/NEJM199211193272115.
38. Cvetanovich GL, Hafler DA. Human regulatory T cells in autoimmune diseases. Curr Opin Immunol. 2010;22(6):753–60. doi:10.1016/j.coi.2010.08.012.
39. Lund JM, Hsing L, Pham TT, Rudensky AY. Coordination of early protective immunity to viral infection by regulatory T cells. Science. 2008;320(5880):1220–4. doi:10.1126/science.1155209.
40. Boettler T, Spangenberg HC, Neumann-Haefelin C, Panther E, Urbani S, Ferrari C, et al. T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol. 2005;79(12):7860–7. doi:10.1128/JVI.79.12.7860-7867.2005.
41. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8(7):523–32. doi:10.1038/nri2343.
42. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med. 2001;193(11):1303–10.
43. Mendez-Lagares G, Jaramillo-Ruiz D, Pion M, Leal M, Munoz-Fernandez MA, Pacheco YM, et al. HIV infection deregulates the balance between regulatory T cells and IL-2-producing CD4 T cells by decreasing the expression of the IL-2 receptor in Treg. J Acquir Immune Defic Syndr. 2014;65(3):278–82. doi:10.1097/QAI.0000000000000092.
44. Boelaert JR, Appelberg R, Gomes MS, Blasi E, Mazzolla R, Grosset J, et al. Experimental results on chloroquine and AIDS-related opportunistic infections. J Acquir Immune Defic Syndr. 2001;26(3):300–1.
45. Orsilles MA, Pieri E, Cooke P, Caula C. IL-2 and IL-10 serum levels in HIV-1-infected patients with or without active antiretroviral therapy. APMIS. 2006;114(1):55–60. doi:10.1111/j.1600-0463.2006.apm_108.x.
46. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4(4):330–6. doi:10.1038/ni904.
47. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299(5609):1057–61. doi:10.1126/science.1079490.
48. Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol. 2003;4(4):337–42. doi:10.1038/ni909.
49. Balandina A, Lecart S, Dartevelle P, Saoudi A, Berrih-Aknin S. Functional defect of regulatory CD4(+)CD25(+) T cells in the thymus of patients with autoimmune myasthenia gravis. Blood. 2005;105(2):735–41. doi:10.1182/blood-2003-11-3900.
50. Itoh M, Takahashi T, Sakaguchi N, Kuniyasu Y, Shimizu J, Otsuka F, et al. Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol. 1999;162(9):5317–26.
51. Shevach EM. Regulatory T cells in autoimmmunity*. Annu Rev Immunol. 2000;18:423–49. doi:10.1146/annurev.immunol.18.1.423.
52. Caramalho I, Lopes-Carvalho T, Ostler D, Zelenay S, Haury M, Demengeot J. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J Exp Med. 2003;197(4):403–11.
53. Sutmuller RP, den Brok MH, Kramer M, Bennink EJ, Toonen LW, Kullberg BJ, et al. Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest. 2006;116(2):485–94. doi:10.1172/JCI25439.
54. Miller Sanders C, Cruse JM, Lewis RE. Toll-like receptor and chemokine receptor expression in HIV-infected T lymphocyte subsets. Exp Mol Pathol. 2010;88(1):26–31. doi:10.1016/j.yexmp.2009.09.006.
55. Edelman AS, Zolla-Pazner S. AIDS: a syndrome of immune dysregulation, dysfunction, and deficiency. FASEB J. 1989;3(1):22–30.
56. Lepe-Zuniga JL, Mansell PW. AIDS: from immunity to infection to autoimmunity. A comprehensive hypothesis of the pathogenesis of the disease. AIDS Res. 1986;2(4):363–8.
57. Kion TA, Hoffmann GW. Anti-HIV and anti-anti-MHC antibodies in alloimmune and autoimmune mice. Science. 1991;253(5024):1138–40.
58. Ziegler JL, Stites DP. Hypothesis: AIDS is an autoimmune disease directed at the immune system and triggered by a lymphotropic retrovirus. Clin Immunol Immunopathol. 1986;41(3):305–13.
59. Lane HC, Masur H, Edgar LC, Whalen G, Rook AH, Fauci AS. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1983;309(8):453–8. doi:10.1056/NEJM198308253090803.
60. Klinman DM, Morse HC 3rd. Characteristics of B cell proliferation and activation in murine AIDS. J Immunol. 1989;142(4):1144–9.
61. Stratton R, Slapak G, Mahungu T, Kinloch-de Loes S. Autoimmunity and HIV. Curr Opin Infect Dis. 2009;22(1):49–56. doi:10.1097/QCO.0b013e328321000600001432-200902000-00009.
62. Marx J. Autoimmunity explored in AIDS pathology. Science. 1991;254(5033):799. doi:10.1126/science.254.5033.799.
63. Haynes BF, Montefiori DC. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev Vaccines. 2006;5(4):579–95. doi:10.1586/14760584.5.4.579.
64. Zandman-Goddard G, Shoenfeld Y. HIV and autoimmunity. Autoimmun Rev. 2002;1(6):329–37.
65. Halpern SD, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347(4):284–7. doi:10.1056/NEJMsb020632.
66. Lambotte O, Lecuroux C, Saez-Cirion A, Barbet C, Shin SY, Boufassa F, et al. Kidney transplantation in an elite HIV controller: limited impact of immunosuppressive therapy on viro-immunological status. J Infect. 2012;64(6):630–3. doi:10.1016/j.jinf.2012.03.001.
67. Uriel N, Jorde UP, Cotarlan V, Colombo PC, Farr M, Restaino SW, et al. Heart transplantation in human immunodeficiency virus-positive patients. J Heart Lung Transplant. 2009;28(7):667–9. doi:10.1016/j.healun.2009.04.005.
68. Toso C, Berney T, Oberholzer J, Chave JP, Martin PY, Zeender E, et al. Kidney-pancreas transplantation in a long-term non-progressor HIV-infected recipient. Am J Transplant. 2003;3(5):631–3.
69. Roland ME, Barin B, Carlson L, Frassetto LA, Terrault NA, Hirose R, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant. 2008;8(2):355–65. doi:10.1111/j.1600-6143.2007.02061.x.
70. Tzakis AG, Cooper MH, Dummer JS, Ragni M, Ward JW, Starzl TE. Transplantation in HIV+ patients. Transplantation. 1990;49(2):354–8.
71. Jacobson SK, Calne RY, Wreghitt TG. Outcome of HIV infection in transplant patient on cyclosporin. Lancet. 1991;337(8744):794.
72. Schwarz A, Offermann G, Keller F, Bennhold I, L’Age-Stehr J, Krause PH, et al. The effect of cyclosporine on the progression of human immunodeficiency virus type 1 infection transmitted by transplantation—data on four cases and review of the literature. Transplantation. 1993;55(1):95–103.
73. Ahuja TS, Zingman B, Glicklich D. Long-term survival in an HIV-infected renal transplant recipient. Am J Nephrol. 1997;17(5):480–2.
74. Roland ME, Stock PG. Review of solid-organ transplantation in HIV-infected patients. Transplantation. 2003;75(4):425–9. doi:10.1097/01.TP.0000046943.35335.18.
75. Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009;360(7):692–8. doi:10.1056/NEJMoa0802905.
76. Allers K, Hutter G, Hofmann J, Loddenkemper C, Rieger K, Thiel E, et al. Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood. 2011;117(10):2791–9. doi:10.1182/blood-2010-09-309591.
77. Verheyen J, Esser S, Kordelas L. More on shift of HIV tropism in stem-cell transplantation with CCR5 delta32/delta32 mutation. N Engl J Med. 2014;371(25):2438. doi:10.1056/NEJMc1412279.
78. Kordelas L, Verheyen J, Beelen DW, Horn PA, Heinold A, Kaiser R, et al. Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. N Engl J Med. 2014;371(9):880–2. doi:10.1056/NEJMc1405805.
79. Hayden EC. Stem-cell transplants may purge HIV. Nature News. http://www.nature.com/news/stem-cell-transplants-may-purge-hiv-1.13297. Accessed 15 Aug 2013.
80. Henrich TJ, Hanhauser E, Sirignano MN, Kuritzkes DR. HIV-1 rebound following allogeneic stem cell transplantation and treatment interruption. In: 21st conference on retroviruses and opportunistic infections, Boston; 2014. p. 3–6.
81. Henrich TJ, Hanhauser E, Li JZ, Heisey A, Abramson JS, Hamdan A, et al. Impact of systemic cytotoxic chemotherapy for malignancies on HIV-1 reservoir persistence. In: 21st conference on retroviruses and opportunistic infections, Boston; 2014.
82. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis. 2006;194(12):1661–71. doi:10.1086/508748.
83. Mann JK, Ndung’u T. HIV-1 vaccine immunogen design strategies. Virol J. 2015;12:3. doi:10.1186/s12985-014-0221-0.
84. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361(23):2209–20. doi:10.1056/NEJMoa0908492.
85. HIV vaccine failure prompts Merck to halt trial. Nature. 2007;449(7161):390. doi:10.1038/449390c.
86. Robb ML. Failure of the Merck HIV vaccine: an uncertain step forward. Lancet. 2008;372(9653):1857–8. doi:10.1016/S0140-6736(08)61593-7.
87. McCarthy M. AIDS vaccine fails in Thai trial. Lancet. 2003;362(9397):1728. doi:10.1016/S0140-6736(03)14886-6.
88. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet. 2008;372(9653):1894–905. doi:10.1016/S0140-6736(08)61592-5.
89. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372(9653):1881–93. doi:10.1016/S0140-6736(08)61591-3.
90. Virgin HW, Walker BD. Immunology and the elusive AIDS vaccine. Nature. 2010;464(7286):224–31. doi:10.1038/nature08898.
91. Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis. 2011;11(7):507–15. doi:10.1016/S1473-3099(11)70098-6.
92. Gray GE, Moodie Z, Metch B, Gilbert PB, Bekker LG, Churchyard G, et al. Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. Lancet Infect Dis. 2014;14(5):388–96. doi:10.1016/S1473-3099(14)70020-9.
93. Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature. 2008;455(7213):613–9. doi:10.1038/nature07352.
94. Fauci AS. The syndrome of Kaposi’s sarcoma and opportunistic infections: an epidemiologically restricted disorder of immunoregulation. Ann Intern Med. 1982;96(6 Pt 1):777–9.
95. Acquired immunodeficiency syndrome. Lancet. 1983;1(8317):162–4.
96. Giorgi JV, Nishanian PG, Schmid I, Hultin LE, Cheng HL, Detels R. Selective alterations in immunoregulatory lymphocyte subsets in early HIV (human T-lymphotropic virus type III/lymphadenopathy-associated virus) infection. J Clin Immunol. 1987;7(2):140–50.
97. Salazar-Gonzalez JF, Moody DJ, Giorgi JV, Martinez-Maza O, Mitsuyasu RT, Fahey JL. Reduced ecto-5′-nucleotidase activity and enhanced OKT10 and HLA-DR expression on CD8 (T suppressor/cytotoxic) lymphocytes in the acquired immune deficiency syndrome: evidence of CD8 cell immaturity. J Immunol. 1985;135(3):1778–85.
98. Fahey JL, Taylor JM, Detels R, Hofmann B, Melmed R, Nishanian P, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med. 1990;322(3):166–72. doi:10.1056/NEJM199001183220305.
99. Basu A, Sanchez TW, Casiano CA. DFS70/LEDGFp75: an enigmatic autoantigen at the interface between autoimmunity, AIDS, and cancer. Front Immunol. 2015;6:116. doi:10.3389/fimmu.2015.00116.
100. Rawson PM, Molette C, Videtta M, Altieri L, Franceschini D, Donato T, et al. Cross-presentation of caspase-cleaved apoptotic self antigens in HIV infection. Nat Med. 2007;13(12):1431–9. doi:10.1038/nm1679.
101. Rowland-Jones S, Dong T. Dying T cells trigger autoimmunity in HIV. Nat Med. 2007;13(12):1413–5. doi:10.1038/nm1207-1413.
102. Stramer SL, Glynn SA, Kleinman SH, Strong DM, Caglioti S, Wright DJ, et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med. 2004;351(8):760–8. doi:10.1056/NEJMoa040085.
103. Donegan E, Stuart M, Niland JC, Sacks HS, Azen SP, Dietrich SL, et al. Infection with human immunodeficiency virus type 1 (HIV-1) among recipients of antibody-positive blood donations. Ann Intern Med. 1990;113(10):733–9.
104. Operskalski EA, Stram DO, Lee H, Zhou Y, Donegan E, Busch MP, et al. Human immunodeficiency virus type 1 infection: relationship of risk group and age to rate of progression to AIDS. Transfusion Safety Study Group. J Infect Dis. 1995;172(3):648–55.
105. Kroner BL, Rosenberg PS, Aledort LM, Alvord WG, Goedert JJ. HIV-1 infection incidence among persons with hemophilia in the United States and western Europe, 1978–1990. Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr. 1994;7(3):279–86.
106. Vojdani A. Molecular mimicry as a mechanism for food immune reactivities and autoimmunity. Altern Ther Health Med. 2015;21(Suppl. 1):34–45.
107. Rao TK, Filippone EJ, Nicastri AD, Landesman SH, Frank E, Chen CK, et al. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med. 1984;310(11):669–73. doi:10.1056/NEJM198403153101101.
108. Debiec H, Lefeu F, Kemper MJ, Niaudet P, Deschenes G, Remuzzi G, et al. Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med. 2011;364(22):2101–10. doi:10.1056/NEJMoa1013792.
109. Fogo AB. Milk and membranous nephropathy. N Engl J Med. 2011;364(22):2158–9. doi:10.1056/NEJMe1103049.
110. Kotler DP, Wang J, Pierson RN. Body composition studies in patients with the acquired immunodeficiency syndrome. Am J Clin Nutr. 1985;42(6):1255–65.
111. Kotler DP, Tierney AR, Wang J, Pierson RN Jr. Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr. 1989;50(3):444–7.
112. Zhao HL, Sun CZ, Jiang WP, Dai ZK, Shi WX, Yang KK, et al. Eight-year survival of AIDS patients treated with Chinese herbal medicine. Am J Chin Med. 2014;42(2):261–74. doi:10.1142/S0192415X14500177.
113. Colebunders R, Francis H, Mann JM, Bila KM, Izaley L, Kimputu L, et al. Persistent diarrhea, strongly associated with HIV infection in Kinshasa, Zaire. Am J Gastroenterol. 1987;82(9):859–64.
114. Dworkin B, Wormser GP, Rosenthal WS, Heier SK, Braunstein M, Weiss L, et al. Gastrointestinal manifestations of the acquired immunodeficiency syndrome: a review of 22 cases. Am J Gastroenterol. 1985;80(10):774–8.
115. Sepkowitz KA, Telzak EE, Carrow M, Armstrong D. Fever among outpatients with advanced human immunodeficiency virus infection. Arch Intern Med. 1993;153(16):1909–12.
116. Lavreys L, Thompson ML, Martin HL Jr, Mandaliya K, Ndinya-Achola JO, Bwayo JJ, et al. Primary human immunodeficiency virus type 1 infection: clinical manifestations among women in Mombasa, Kenya. Clin Infect Dis. 2000;30(3):486–90. doi:10.1086/313718.
117. Daar ES, Little S, Pitt J, Santangelo J, Ho P, Harawa N, et al. Diagnosis of primary HIV-1 infection. Los Angeles County primary HIV infection recruitment network. Ann Intern Med. 2001;134(1):25–9.
118. Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, White AC Jr, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS. 2005;19(4):399–406.
119. Florence E, Bottieau E, Lynen L, Colebunders R. Patients with HIV infection and fever: a diagnostic approach. Acta Clin Belg. 2002;57(4):184–90. doi:10.1179/acb.2002.040.
120. Pao V, Lee GA, Grunfeld C. HIV therapy, metabolic syndrome, and cardiovascular risk. Curr Atheroscler Rep. 2008;10(1):61–70.
121. Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005;165(10):1179–84. doi:10.1001/archinte.165.10.1179.
122. Woerle HJ, Mariuz PR, Meyer C, Reichman RC, Popa EM, Dostou JM, et al. Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes. 2003;52(4):918–25.
123. Spollett GR. Hyperglycemia in HIV/AIDS. Diabetes Spectr. 2006;19:163–6.
124. Hengel RL, Watts NB, Lennox JL. Benign symmetric lipomatosis associated with protease inhibitors. Lancet. 1997;350(9091):1596.
125. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353(9170):2093–9. doi:10.1016/S0140-6736(98)08468-2.
126. Macallan DC, McNurlan MA, Milne E, Calder AG, Garlick PJ, Griffin GE. Whole-body protein turnover from leucine kinetics and the response to nutrition in human immunodeficiency virus infection. Am J Clin Nutr. 1995;61(4):818–26.
127. Macallan DC. Wasting in HIV infection and AIDS. J Nutr. 1999;129(1S Suppl.):238S–42S.
128. Cohen J. The emerging race to cure HIV infections. Science. 2011;332(6031):784–5. doi:10.1126/science.332.6031.784.
129. Gurtler L. Difficulties and strategies of HIV diagnosis. Lancet. 1996;348(9021):176–9.
130. Guillevin L. Vasculitides in the context of HIV infection. AIDS. 2008;22(Suppl. 3):S27–33. doi:10.1097/01.aids.0000327513.53255.1700002030-200809003-00005.
131. Eisenstat BA, Wormser GP. Seborrheic dermatitis and butterfly rash in AIDS. N Engl J Med. 1984;311(3):189. doi:10.1056/NEJM198407193110312.
132. Feigal DW, Katz MH, Greenspan D, Westenhouse J, Winkelstein W Jr, Lang W, et al. The prevalence of oral lesions in HIV-infected homosexual and bisexual men: three San Francisco epidemiological cohorts. AIDS. 1991;5(5):519–25.
133. Hecht FM, Busch MP, Rawal B, Webb M, Rosenberg E, Swanson M, et al. Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS. 2002;16(8):1119–29.
134. Justice AC, Feinstein AR, Wells CK. A new prognostic staging system for the acquired immunodeficiency syndrome. N Engl J Med. 1989;320(21):1388–93. doi:10.1056/NEJM198905253202106.
135. Famularo G, Moretti S, Marcellini S, Nucera E, De Simone C. CD8 lymphocytes in HIV infection: helpful and harmful. J Clin Lab Immunol. 1997;49(1):15–32.
136. Cameron ML, Granger DL, Matthews TJ, Weinberg JB. Human immunodeficiency virus (HIV)-infected human blood monocytes and peritoneal macrophages have reduced anticryptococcal activity whereas HIV-infected alveolar macrophages retain normal activity. J Infect Dis. 1994;170(1):60–7.
137. Barron MA, Blyveis N, Palmer BE, MaWhinney S, Wilson CC. Influence of plasma viremia on defects in number and immunophenotype of blood dendritic cell subsets in human immunodeficiency virus 1-infected individuals. J Infect Dis. 2003;187(1):26–37. doi:10.1086/345957.
138. Donaghy H, Pozniak A, Gazzard B, Qazi N, Gilmour J, Gotch F, et al. Loss of blood CD11c(+) myeloid and CD11c(−) plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load. Blood. 2001;98(8):2574–6.
139. Cai Q, Huang XL, Rappocciolo G, Rinaldo CR Jr. Natural killer cell responses in homosexual men with early HIV infection. J Acquir Immune Defic Syndr. 1990;3(7):669–76.
140. Apoil PA, Puissant B, Roubinet F, Abbal M, Massip P, Blancher A. FOXP3 mRNA levels are decreased in peripheral blood CD4+ lymphocytes from HIV-positive patients. J Acquir Immune Defic Syndr. 2005;39(4):381–5.
141. Quinnan GV Jr, Siegel JP, Epstein JS, Manischewitz JF, Barnes S, Wells MA. Mechanisms of T-cell functional deficiency in the acquired immunodeficiency syndrome. Ann Intern Med. 1985;103(5):710–4.
142. Stoiber H, Kacani L, Speth C, Wurzner R, Dierich MP. The supportive role of complement in HIV pathogenesis. Immunol Rev. 2001;180:168–76.
143. Montefiori DC. Role of complement and Fc receptors in the pathogenesis of HIV-1 infection. Springer Semin Immunopathol. 1997;18(3):371–90.
144. Schulz TF, Boshoff CH, Weiss RA. HIV infection and neoplasia. Lancet. 1996;348(9027):587–91. doi:10.1016/S0140-6736(95)11033-X.
145. Carne CA, Weller IV, Loveday C, Adler MW. From persistent generalised lymphadenopathy to AIDS: who will progress? Br Med J (Clin Res Ed). 1987;294(6576):868–9.
146. Aboulafia DM, Meneses M, Ginsberg S, Siegel MS, Howard WW, Dezube BJ. Acute myeloid leukemia in patients infected with HIV-1. AIDS. 2002;16(6):865–76.
147. Grulich AE, Li Y, McDonald A, Correll PK, Law MG, Kaldor JM. Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS. 2002;16(8):1155–61.
148. Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood. 2006;108(12):3786–91. doi:10.1182/blood-2006-05-024109.
149. Nagaiah G, Stotler C, Orem J, Mwanda WO, Remick SC. Ocular surface squamous neoplasia in patients with HIV infection in sub-Saharan Africa. Curr Opin Oncol. 2010;22(5):437–42. doi:10.1097/CCO.0b013e32833cfcf9.
150. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370(9581):59–67. doi:10.1016/S0140-6736(07)61050-2.
151. Freedberg KA, Scharfstein JA, Seage GR 3rd, Losina E, Weinstein MC, Craven DE, et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA. 1998;279(2):130–6.
152. Rigby R. Out of control. BMJ. 1995;310(6992):1475.
153. Samuel R, Bettiker RL, Suh B. AIDS related opportunistic infections, going but not gone. Arch Pharm Res. 2002;25(3):215–28.
154. Siberry GK, Abzug MJ, Nachman S, Brady MT, Dominguez KL, Handelsman E, et al. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. Pediatr Infect Dis J. 2014;32(Suppl. 2):i-KK4. doi:10.1097/01.inf.0000437856.09540.1100006454-201311002-00001.
155. Sarraf D, Ernest JT. AIDS and the eyes. Lancet. 1996;348(9026):525–8. doi:10.1016/S0140-6736(96)05209-9.
156. Holland GN, Pepose JS, Pettit TH, Gottlieb MS, Yee RD, Foos RY. Acquired immune deficiency syndrome. Ocular manifestations. Ophthalmology. 1983;90(8):859–73.
157. Calmy A, Hirschel B, Cooper DA, Carr A. Clinical update: adverse effects of antiretroviral therapy. Lancet. 2007;370(9581):12–4. doi:10.1016/S0140-6736(07)61027-7.
158. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet. 2000;356(9239):1423–30. doi:10.1016/S0140-6736(00)02854-3.
159. Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(4):251–61. doi:10.1016/S1473-3099(10)70026-8.
160. Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987;317(4):192–7. doi:10.1056/NEJM198707233170402.
161. Kingsley LA, Detels R, Kaslow R, Polk BF, Rinaldo CR Jr, Chmiel J, et al. Risk factors for seroconversion to human immunodeficiency virus among male homosexuals. Results from the Multicenter AIDS Cohort Study. Lancet. 1987;1(8529):345–9.
162. Marmor M, Friedman-Kien AE, Laubenstein L, Byrum RD, William DC, D’Onofrio S, et al. Risk factors for Kaposi’s sarcoma in homosexual men. Lancet. 1982;1(8281):1083–7.
163. El-Sadr WM, Mayer KH, Hodder SL. AIDS in America—forgotten but not gone. N Engl J Med. 2010;362(11):967–70. doi:10.1056/NEJMp1000069.
164. Grossman WJ, Verbsky JW, Tollefsen BL, Kemper C, Atkinson JP, Ley TJ. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood. 2004;104(9):2840–8. doi:10.1182/blood-2004-03-0859.
165. Bopp T, Becker C, Klein M, Klein-Hessling S, Palmetshofer A, Serfling E, et al. Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med. 2007;204(6):1303–10. doi:10.1084/jem.20062129.
166. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007;204(6):1257–65. doi:10.1084/jem.20062512.
167. Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol. 2007;8(12):1353–62. doi:10.1038/ni1536.
168. Serra P, Amrani A, Yamanouchi J, Han B, Thiessen S, Utsugi T, et al. CD40 ligation releases immature dendritic cells from the control of regulatory CD4+CD25+ T cells. Immunity. 2003;19(6):877–89.
169. Misra N, Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol. 2004;172(8):4676–80.
170. Calabrese LH, Estes M, Yen-Lieberman B, Proffitt MR, Tubbs R, Fishleder AJ, et al. Systemic vasculitis in association with human immunodeficiency virus infection. Arthritis Rheum. 1989;32(5):569–76.
171. Gherardi R, Belec L, Mhiri C, Gray F, Lescs MC, Sobel A, et al. The spectrum of vasculitis in human immunodeficiency virus-infected patients.A clinicopathologic evaluation. Arthritis Rheum. 1993;36(8):1164–74.
172. Allers K, Hutter G, Hofmann J, Loddenkemper C, Rieger K, Thiel E, et al. Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood. 2010;117(10):2791–9. doi:10.1182/blood-2010-09-309591.